A JAMA Internal Medicine study highlighted increased gallbladder disease among semaglutide users, and in 2023, the FDA required label changes to reflect serious gastrointestinal risks
PlexusDx serves all 50 states without insurance, making prescription GLP-1 therapy accessible to those who would otherwise turn to unproven alternatives
Puglisi S, Rossini A, Poli R et al (2021) Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system
Understanding this distressing symptom requires a deep clinical dive into esophageal motility, mucosal irritation, and the neuro-muscular reflexes of the upper digestive tract
Notably, significant reductions were observed in CAT total and energy score at 4 weeks and CAT total, cough, and dyspnea scores at 8 weeks of treatment